• Aucun résultat trouvé

Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

N/A
N/A
Info
Télécharger
Protected

Academic year: 2022

Partager "Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials"

Copied!
1
0
0

Chargement.... (Voir le texte intégral maintenant)

Texte intégral

(1)

ERRATUM

Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Sandra Adsit.Enrique Rivas Zaldivar.Howard Sofen.

Ignacio Dei-Cas.Ce´sar Maldonado-Garcı´a.Elkin O. Pen˜aranda. Luı´s Puig.Xiangyi Meng.Todd Fox.Adriana Guana

Published online: June 6, 2017

ÓThe Author(s) 2017. This article is an open access publication

Erratum to: Adv Ther

DOI 10.1007/s12325-017-0521-z

Unfortunately, the given name and family name of the co-author Dr. Ce´sar Maldonado Garcı´a were incorrectly published in the origi- nal publication. The correct given name and family name should read as ‘Ce´sar’ and ‘Mal- donado-Garcı´a’, respectively.

Also Dr. Ce´sar Maldonado-Garcı´a’s affiliation should read as follows:

C. Maldonado-Garcı´a

Centro Dermatolo´gico ‘‘Dr. Ladislao de la Pas- cua’’, Mexico City, Mexico

The original article has been corrected.

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/

by-nc/4.0/), which permits any non- commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The online version of the original article can be found under doi:10.1007/s12325-017-0521-z.

S. Adsit (&)

TCR Medical Corporation, San Diego, CA, USA e-mail: sadsit@therapeuticsinc.com

E. R. Zaldivar

Dermos, Guatemala City, Guatemala H. Sofen

UCLA School of Medicine, Los Angeles, CA, USA I. Dei-Cas

Halitus, Buenos Aires, Argentina C. Maldonado-Garcı´a

Centro Dermatolo´gico ‘‘Dr. Ladislao de la Pascua’’, Mexico City, Mexico

E. O. Pen˜aranda

Riesgo de Fractura S.A., Bogota, Colombia L. Puig

Hospital de la Santa Creu i Sant Pau, Universitat Auto`noma de Barcelona, Barcelona, Spain X. MengA. Guana

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

T. Fox

Novartis Pharma AG, Basel, Switzerland Adv Ther (2017) 34:1772

DOI 10.1007/s12325-017-0563-2

Références

Télécharger maintenant ( PDF - 1 Page - 338.67 KB )

Documents relatifs

The Effect of Biologic Therapies on the Risk of Suffering a Myocardial Infarction (MI) in Patients with Moderate to Severe Psoriasis

The aim was to test for a protective factor in biologic therapies as patients with moderate to severe psoriasis have been reported to be at a higher risk of

ABSTRACT DermatologyLifeQualityIndexinPatientswithModerate-to-SeverePlaquePsoriasisTreatedwithBrodalumaborUstekinumab

In an analysis of data pooled from two randomised, controlled, phase 3 trials of patients with moderate-to-severe plaque psoriasis, a significantly greater reduction (improvement)

Evaluating practice patterns for managing moderate to severe plaque psoriasis: Role of the family physician

• Current psoriasis guidelines recommend prescription oral or injectable medications or phototherapy as primary treatment for moderate to severe psoriasis or extensive

Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis : a phase 2 randomized control trial

For example, the group that received 7 mg/kg throughout the trial had a lower mean age, milder Myasthenia Gravis Foundation of America disease classification scores, and lower QMG

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy : an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies

Here, using integrated data from UltIMMa-1 and UltIMMa-2, we assessed the impact of baseline patient demographics, disease characteristics and prior biologic exposure on the efficacy

Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis

The assay LLOD, LLOQ and cut-off values for detection and quantification for the anti-guselkumab antibody bridging and ACE assay were determined using a panel of 25

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative

Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD

The Prospective Random- ized Placebo-Controlled Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) was a prospective, multicenter trial conducted by the